Larimar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Larimar Therapeutics

10/08/2023 16:14

* Larimar Therapeutics Inc  LRMR.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 19 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Larimar Therapeutics Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 22.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Larimar Therapeutics Inc shares had risen by 27.8% this
quarter and lost 3.1% so far this year.
    * The company reported a quarterly loss of $8.37 million.
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $14.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 03:14 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.19          -0.19          Met
 Mar. 31 2023      -0.25          -0.15          Beat
 Dec. 31 2022      -0.27          -0.21          Beat
 Sep. 30 2022      -0.42          -0.37          Beat